Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. | AstraZeneca’s Imfinzi has proven it can help ...

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Imfinzi be used in combination with ...

The FDA nod marked the first time an immunotherapy regimen has been approved in a perioperative setting, which makes Imfinzi a potential transformative option for the MIBC patient population.

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...